Trials
Ongoing trials:
First line of treatment
- Ixazomib-Revlimid-Dexamethason in first line for the young
- Daratumumab vs observation in smouldering myeloma
- KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
- HOVON129 - Treatment of primary plasma cell leukemia
Relapse or refractory, patient not eligible for ASCT
- Panorama 3: Panobinostat-Velcade-Dexamethason randomized to different doses in relapse treatment
- Melflufen vs Pomalidomide in relapsed myeloma
- Cobimetinib +/- venetoclax +/- atezolizumab in relapsed myeloma
- Ixazomib vs Pomalidomide in relapsed myeloma
- Venetoclax for patients with 11;14-translocation at relapse
- Phase-4-study on treatment with filzomib in routine practice
Upcoming trials:
- Hovon147 - Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.
- bb2121 - A phase 3, multicenter, randomized, openlabel study to compare the efficacy and safety of BB2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM) (KarMMa-3)
- Cooral - Cryoprevention of chemotherapy-induced oral mucositis after autologous stem cell transplantation, a randomized study
- Titanium1 – Phase 1/2 open-label trial of tinostamustine conditioning and autologous stem cell transplantation for salvage treatment in relapsed/refractory multiple myeloma
- Perseus - A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy